- Home
- NRXP vs COEP Comparison
NRXP vs COEP Comparison
Compare NRXP & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- COEP
- Stock Information
- Founded
- NRXP 2015
- COEP 2017
- Country
- NRXP United States
- COEP United States
- Employees
- NRXP N/A
- COEP N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRXP Health Care
- COEP Health Care
- Exchange
- NRXP Nasdaq
- COEP Nasdaq
- Market Cap
- NRXP 32.6M
- COEP 27.4M
- IPO Year
- NRXP N/A
- COEP N/A
- Fundamental
- Price
- NRXP $3.24
- COEP $9.47
- Analyst Decision
- NRXP Strong Buy
- COEP
- Analyst Count
- NRXP 4
- COEP 0
- Target Price
- NRXP $28.50
- COEP N/A
- AVG Volume (30 Days)
- NRXP 204.8K
- COEP 38.0K
- Earning Date
- NRXP 08-13-2025
- COEP 08-15-2025
- Dividend Yield
- NRXP N/A
- COEP N/A
- EPS Growth
- NRXP N/A
- COEP N/A
- EPS
- NRXP N/A
- COEP N/A
- Revenue
- NRXP N/A
- COEP $62,874.00
- Revenue This Year
- NRXP N/A
- COEP N/A
- Revenue Next Year
- NRXP N/A
- COEP N/A
- P/E Ratio
- NRXP N/A
- COEP N/A
- Revenue Growth
- NRXP N/A
- COEP N/A
- 52 Week Low
- NRXP $1.10
- COEP $2.31
- 52 Week High
- NRXP $6.01
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- NRXP 53.62
- COEP 62.24
- Support Level
- NRXP $2.90
- COEP $7.25
- Resistance Level
- NRXP $3.53
- COEP $9.90
- Average True Range (ATR)
- NRXP 0.20
- COEP 0.63
- MACD
- NRXP -0.04
- COEP 0.26
- Stochastic Oscillator
- NRXP 58.73
- COEP 85.62
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.